

IT MATTERS.



EDITION SPOTLIGHT

15 ASTERA'S NEWEST TOMS RIVER LOCATION OPENS!
Cancer care for those we love

24 MINIMIZING RADIATION SIDE EFFECTS
with Prostate Spacer Balloons

33 FIRST PATIENT IN THE WORLD ENROLLED IN
Clinical Trial IDEate-Lung02

FIRST PAGE

Contents



4



18



28

Articles

- 03. Message From Our Chief Medical Officer
- 04. Barry's Triumph Over Lymphoma: A Journey of Clinical Trial Success
- 06. Dr. Siu-Long Yao Joins Astera Cancer Care
- 08. Understanding Prostate Cancer: Symptoms, Diagnosis, Treatment, and Prevention
- 15. Astera Cancer Care Opens New Location in Toms River
- 16. Astera Cancer Care's Infusion and Pharmacy Services: It Matters
- 18. Vivica's Fight Against Lymphoma
- 20. Clinician Engagement Strategies to Increase Palliative Care Access in a Multi-Site Community Oncology Practice: A Patient-Focused Perspective
- 24. Minimizing Radiation Side Effects with Prostate Spacer Balloons
- 26. The Evolving Landscape of Breast Cancer Treatment
- 28. American Cancer Society's Making Strides Walks Jersey City & Edison
- 33. First Patient in the World Enrolled in Clinical Trial IDEate-Lung02
- 34. 2024 New Physicians
- 36. Patient Reviews



On the Cover
The Astera Team Together as One!

Message From Our Chief Medical Officer

Welcome to this edition of It Matters, where each article reflects Astera Cancer Care's commitment to enhancing quality of life for patients and their families. Our mission is to transform the approach to cancer care and blood disorders, providing treatments that are patient-focused, research-driven, and rooted in compassion.

We are thrilled to share exciting news about Astera's growth as we expand to serve even more communities across New Jersey. We are already seeing patients in Toms River and look forward to opening a state-of-the-art office in 2025.

In this issue, you'll find a variety of stories, insights, and resources designed to inform and support you on your healthcare journey. We will share the latest updates on clinical trials, including promising advancements from the IDEate-Lung02 study. Clinical trial access is just one way we're working to bring innovative, evidence-based treatments to our community.


Our Patient Stories section features inspiring accounts of resilience, with Barry's journey offering a firsthand look at the strength that unites our patients. Astera's dedication to comprehensive care extends to supportive services like palliative care and social work. We also have a heroic team working behind the scenes to ensure timely approval and delivery of oral medications and infusions. This issue offers updates on these critical areas, highlighting the compassionate care and expertise available at every step.

We've also included expert insights from Dr. Sundus Abbasi on breast cancer prevention and Dr. Aamer Farooq on prostate health, empowering you with the knowledge to make informed choices.

Thank you for being part of our community. We're here to support you, and we hope this issue of It Matters provides the resources, inspiration, and knowledge to make your healthcare journey smoother and more empowered.

Warm regards,

Ellen Ronnen, MD
Chief Medical Officer



Barry's

Triumph Over Lymphoma:

A Journey of Clinical Trial Success

In October 2012, Barry discovered a lump under his arm, a moment that would change his life. Initially, his doctor didn't see it as anything serious, but a follow-up in December revealed that the lump was persistent, prompting a chest X-ray. This X-ray indicated something pressing against Barry's windpipe, which led to further tests, including a CAT scan. In January 2013, at the age of 50, Barry was diagnosed with grade one follicular B cell lymphoma, a slow-growing but chronic form of cancer. Faced with uncertainty, Barry pushed for answers and a treatment plan as soon as possible. His primary care physician referred him to Dr. Craig Lampert, someone he personally trusted and would send his own father to.

Dr. Lampert reassured Barry right from their first phone call: although cancer was a serious diagnosis, this type of lymphoma was manageable. The slow-growing nature of the disease allowed for a "watch-and-wait" approach, avoiding immediate treatment and giving Barry time to maintain a normal life. With Dr. Lampert's calm demeanor and clear communication, Barry felt like a weight had been lifted off his shoulders. The plan was in place, and Barry felt confident knowing there would be future treatment options if and when his condition changed.

For three years, Barry lived symptom-free, without any need for treatment. In January 2016, a lymph node started to press against his airway, prompting his first round of chemotherapy and immunotherapy. Barry's body responded well, and after six months of treatment, he was back to living a normal life, even resuming work and maintaining an active lifestyle.

In July 2020, Barry faced a relapse during the COVID-19 pandemic. Once again, he turned to his trusted care team, now led by Dr. Bruno Fang, who introduced him to advanced treatment options only available at institutions with robust research programs. This time, the approach involved combining well-established therapies with a promising new drug that offered a more targeted and less toxic option for patients like Barry.

The ability to access cutting-edge treatments was pivotal for Barry. He received care that provided a highly effective treatment plan, allowing him to maintain his quality of life even during a challenging time. With his care team's support, he managed the complexities of treatment during the pandemic, balancing safety with the need for critical care.


Throughout the trial, Barry felt exceptionally well-supported by Dr. Fang and the clinical trial team. They provided not only top-tier cancer care but also guidance through the complexities of the pandemic. Barry completed his last cycle of treatment in July of 2023. The trial allowed Barry to live his life with minimal side



effects, and he even joked with his doctors about having nothing to complain about during his treatment.


Reflecting on his journey, Barry emphasized how critical it was to have a clear treatment plan and a supportive medical team. He shared that living with lymphoma has taught him to "live in fractions"—to focus on the next scan, the next treatment, and the immediate future, rather than long-term planning. Although life with lymphoma has its uncertainties, Barry has maintained an active lifestyle and continued his work as a mechanical technician and union president, never letting the disease slow him down.

Barry's story is one of resilience, hope, and trust in the medical advancements made possible through clinical trials. With access to the latest clinical trials through Astera's robust trial program, Barry found innovative treatment options tailored to his needs. His message to others facing a cancer diagnosis is clear: once you have a plan in place, the fear subsides, and with the right support, life goes on.



Dr. Siu-Long Yao

Joins Astera Cancer Care



Siu-Long Yao, MD

Dr. Siu-Long Yao, a dedicated oncologist and clinical researcher, has spent much of his life immersed in the intricate world of medical science. As a college student in the mid-1980s, he watched his brother battle testicular cancer during an era when treatment options were limited,

and side effects were overwhelming. The experience not only shifted his career path from chemistry to medicine but also sparked a lifelong mission: to improve cancer treatment and patient care.

Dr. Yao was a curious and problem-solving individual from an early age. Growing up in a household influenced by his father, a doctor, and his mother, a nurse, he was surrounded by examples of care and compassion. But it was his brother's experience with cancer that catalyzed his decision to pursue oncology. "Seeing the side effects my brother endured made me realize there had to be a better way," he recalls. This sentiment became the foundation for his career, inspiring him to work toward treatments that could alleviate pain and improve outcomes for patients worldwide.

This desire to connect more deeply with patients brought him to Astera Cancer Care, where he found a community that mirrored his values. He was drawn to the collaborative,

multidisciplinary approach of the practice, which parallels an academic medical center, with the most intellectually driven team he's encountered. Unlike traditional private practices, where doctors often operate independently, Astera fosters teamwork and consultation. "Everyone here is an expert in their specialty, and we all come together to ensure the best care for each patient," he explains.

Dr. Yao views oncology as one of the most intellectually demanding and rewarding specialties. "In oncology, you have to use everything you know," he says. "Cancer affects nearly every organ, so you're constantly applying the full spectrum of medical knowledge." Beyond its breadth, the field's constant evolution appeals to his love for puzzles and challenges. "Oncology is like solving the most difficult puzzle, it's ever-changing, science-heavy, and requires staying on the cutting edge."

Clinical research has been a cornerstone of Dr. Yao's career, offering him an opportunity to contribute to medical advancements on a global scale. His work on groundbreaking drugs, used for various cancers, exemplifies his impact on the world of medicine. "Clinical trials are the future," he asserts. "They are the gateway to the next breakthroughs, and the results benefit not only the patients in the trials but millions of others worldwide."

Despite the challenges inherent in clinical trials; meticulous testing, regulatory hurdles,

and patient recruitment, Dr. Yao finds the work deeply fulfilling. He approaches trial selection with a personal lens, imagining each drug as if it were for his own family. "I ask myself, is this the best shot for my parents, my brother, or someone I love?" This mindset ensures his focus remains on safety, efficacy, and patient well-being.

"In oncology, we're not just solving scientific puzzles; we're creating hope and that's the most important work I could ever do." Dr. Siu-Long Yao

At the core of Dr. Yao's philosophy is personalized medicine. He believes that every patient deserves a tailored approach that respects their unique social, cultural, and medical circumstances. Before meeting a patient, he carefully reviews their case, then works collaboratively to create a treatment plan that aligns with their priorities. "Some patients value quality of life above all else, while others prioritize longevity," he says. "Our job is to listen, respect their choices, and find the best path forward together."

Beyond medicine, Dr. Yao finds parallels between his work and his passion for trail running. Much like navigating uncharted paths in the wilderness, his research and patient care require venturing into the unknown, solving problems, and overcoming obstacles. "It's about exploring and pushing boundaries, whether in a forest or a clinical trial," he says.

Dr. Yao remains optimistic about the future of oncology and clinical research. He envisions a world where personalized medicine, driven by advancements in research, becomes the standard of care. His contributions to the field have already changed countless lives, but

for him, the work is never finished. "We have to keep pushing forward," he says. "There's always something new to discover, a better treatment to develop, and a patient who needs hope."

For Dr. Yao, oncology isn't just a career - it's a calling. Each patient he treats, each trial he leads, and each breakthrough he contributes to is part of a larger mission to transform cancer care across the globe. He dreams of a future where no one has to endure the side effects his brother faced, where treatments are kinder and outcomes brighter.

"Whether it's on a trail or in a lab, the goal is the same: to push boundaries, explore new possibilities, and create a better path forward," he says. "In oncology, we're not just solving scientific puzzles; we're creating hope and that's the most important work I could ever do."

Dr. Siu-Long Yao, MD, FACP, is a board-certified hematologist-oncologist with over 20 years of clinical experience and a distinguished career in advancing cancer care. Joining Astera Cancer Care in September 2024, he brings over 17 years of expertise in clinical trials, including leadership as Vice President at Sun Pharma, where he directed the development of innovative oncology treatments. Dr. Yao mentors future oncologists and contributes to educational and research advancements. He also serves as Medical Director of Clinical Research at Astera Cancer Care. A Yale-educated physician, Dr. Yao completed his residency at Dartmouth and a fellowship at Johns Hopkins, building a strong foundation in cancer care and research. Fluent in English and Mandarin, he is committed to improving patient outcomes and shaping the future of oncology across the globe.

Understanding Prostate Cancer:

Symptoms, Diagnosis, Treatment, and Prevention

By Dr. Aamer Farooq



Aamer Farooq, MD

Prostate cancer is a type of cancer that forms in the prostate gland, a small walnut-shaped gland in men located below the bladder and in front of the rectum. Prostate cancer happens when normal cells in the prostate gland change into abnormal cells and grow out of control. The prostate gland produces fluid that is part of semen. This gland sits below the bladder and in front of the rectum and forms a ring around the urethra, the tube that carries urine out of the body. Prostate cancer occurs most often in males 50 years and older. Although prostate cancer is very common, most people do not succumb to it. This is because prostate cancer usually grows very slowly.

Prostate cancer is among the most common cancers in males worldwide, with an estimated 1,600,000 cases and 366,000 deaths annually. In the United States, 11 percent of males are diagnosed with prostate cancer over their lifetime, with the incidence generally rising with age. There are an estimated 268,490 cases and 34,500 deaths annually. The overall five-year survival rate is over 98 percent. Among males 45 to 74, the incidence rate was stable from 2004 to 2010 and then increased significantly from 2010 to 2018 (annual percentage change of 5.3 percent). In males 75 years or older, the incidence rate decreased from 2004 to 2011 and then increased from 2011 to 2018 (annual percentage change of 6.5 percent). Prostate cancer mortality rates have declined in the United States between 1992 and 2017, decreasing from 39 to 19 per 100,000 persons.

Symptoms

In its early stages, prostate cancer often has no symptoms. When symptoms do occur, they can be similar to those of an enlarged prostate or benign prostatic hyperplasia (BPH).

Some possible symptoms of prostate cancer include:

Urinary problems:

- Frequent urination, especially at night
- Difficulty starting or stopping urination
- Weak or interrupted urine flow
- Pain or burning during urination
- Blood in the urine (hematuria)

Sexual problems:

- Erectile dysfunction
- Painful ejaculation
- Blood in the semen

Other symptoms:

- Pain in the lower back, hips, or upper thighs
- Unexplained weight loss
- Fatigue

Causes

The exact cause of prostate cancer is unknown, but several factors may increase the risk, including:

- **Age:** The risk of prostate cancer increases with age.
- **Family history:** Men with a father or brother who has had prostate cancer are at increased risk. Genetic mutations like BRCA1-2, SPOP, HOXB13, CHEK2, PTEC, ATM etc can increase risk of prostate cancer.
- **Race:** African American men are more likely to develop prostate cancer than men of other races.
- **Diet:** A diet high in fat and red meat may increase the risk of prostate cancer. Other factors, such as hormone levels and obesity, have been studied with the goal of developing strategies to reduce the risk of prostate cancer with mixed data.

Diagnosis

If you experience any of these symptoms, it is important to see your doctor for a diagnosis. Your doctor may perform a digital rectal exam (DRE) to assess for any abnormalities in the prostate gland. You may also need a prostate-specific antigen (PSA) test, a blood test that measures the level of PSA in your blood. An elevated PSA level may indicate prostate cancer, but it can also be caused by other conditions, such as BPH.

Age-specific reference ranges are:

- 40 to 49 years - 0 to 2.5 ng/mL
- 50 to 59 years - 0 to 3.5 ng/mL
- 60 to 69 years - 0 to 4.5 ng/mL
- 70 to 79 years - 0 to 6.5 ng/mL

If your PSA level is elevated or if your DRE is abnormal, your doctor may recommend further testing, such as a prostate biopsy. A biopsy involves removing a small piece of tissue from the prostate gland for examination under a microscope.

Multiple molecular prognostic tests are emerging specifically with an aim to better risk stratify both untreated and treated males with localized prostate cancer.

The genomic prostate score (Oncotype Dx Genomic Prostate Score) and genomic classifier (Decipher) are multimarker tests that are specific to prostate cancer, are commercially available, and are recommended by expert groups for risk stratification in clinically localized disease.

Major technical improvements in multiparametric prostate magnetic resonance imaging (MRI) with the standard approach to interpretation using the prostate imaging reporting and data system version 2 (PI-RADS v2) have rapidly expanded the role of MRI in prostate cancer management in many clinical contexts, both prior to and following diagnosis.

PET PSMA is the latest scan to detect metastatic disease.

Understanding Prostate Cancer:

Symptoms, Diagnosis, Treatment, and Prevention

By Dr. Aamer Farooq

continued



Treatment:

Treatment for prostate cancer depends on the stage of the cancer, your overall health, and your personal preferences. For purposes of selecting treatment, newly diagnosed prostate cancer is risk stratified based on digital rectal examination, serum PSA, prostate biopsy, and imaging studies. In some cases, assessment for germline alterations in homologous recombination DNA repair genes and tissue-based gene expression classifiers also contributes. Based on this information, patients can be divided into several categories, which provide the basis for treatment decisions.

Treatment options may include:

- **Active surveillance:** For early-stage, low-risk prostate cancer that is not likely to spread, active surveillance may be an option. This involves monitoring the cancer with regular PSA tests and DREs.
- **Surgery:** Surgery to remove the prostate gland (prostatectomy) may be an option for localized high-risk prostate cancer. Surgery is done by a Urologist.
- **Radiation therapy:** Radiation therapy uses high-energy rays to kill cancer cells. It may be used to treat localized prostate cancer or to relieve symptoms of advanced prostate cancer. Sometimes, hormone therapy shots (Lupron) are done along with radiation therapy to improve the chances of cure in early-stage high-risk prostate cancer.
- **Hormone therapy:** Hormone therapy is the mainstay of treatment if prostate cancer recurs after curative intent local treatments like surgery or radiation. Hormone therapy reduces the amount of testosterone in the body, which can slow the growth of prostate cancer cells as testosterone is needed for prostate cancer cells to grow. Hormone therapy is done by injections like Lupron every 3 months or PO alternatives like Elagolix. This is called chemical castration. The alternative is surgical castration (removal of testes), which is still used in certain situations when compliance with chemical castration is not possible, or chemical castration is not affordable. To further enhance the impact of testosterone reduction, targeted therapies like Zytiga (which inhibits the production of androgen from the prostate gland, adrenal gland, the testes, and skin fat cells) or Xtandi (or Erleada, Nubeqa), which acts as androgen receptor inhibitors, are used to make hormonal therapy/chemical castration more effective. Eventually, at some point, prostate cancer can become castrate-resistant when androgen deprivation therapy is not effective and further systemic therapies like chemotherapy are needed.
- **Chemotherapy:** Chemotherapy uses drugs to kill cancer cells. It is typically used to treat advanced prostate cancer. Commonly used chemotherapies to treat prostate cancer include Taxotere and Cabazitaxol. Other regimens like Carboplatin, Etoposide with immunotherapy like Tecentriq are used if cancer cells become poorly differentiated and start behaving like neuroendocrine cancer.
- **Targeted therapies.** In the case of prostate cancer with a genetic mutation like BRCA, targeted therapies like Olaparib are used.

Understanding Prostate Cancer:

Symptoms, Diagnosis, Treatment, and Prevention

By Dr. Aamer Farooq

continued

Treatment options (continued):

- Sipuleucel-T is an option for patients with asymptomatic or minimally symptomatic slowly progressive metastatic CRPC (Castration-Resistant Prostate Cancer) who lack visceral (especially hepatic) metastasis or cancer pain requiring opioids. Significant declines in prostate-specific antigen (PSA) or radiographically detectable objective antitumor responses are unlikely to occur. As a result, this treatment is not appropriate for those with high-burden, highly symptomatic disease.
- For males with CRPC and bone metastases, an osteoclast inhibitor (denosumab or zoledronic acid) is indicated to prevent or delay skeletal complications in patients with bone metastases.
- Radium-223 – In addition to its role in treating symptoms (i.e., pain) caused by known bone metastases, Ra-223 has been demonstrated to significantly decrease the incidence of symptomatic skeletal events in patients with symptomatic bone metastases.
- For individuals with taxane and androgen receptor pathway inhibitor-refractory, PSMA-positive, metastatic CRPC, we offer lutetium Lu-177 vipivotide tetraxetan rather than Radium-223.
- Pembrolizumab is an option for the treatment of patients with metastatic CRPC who have tumors with dMMR or high levels of TMB (≥ 10 mutations per megabase) that have progressed following prior treatment and for whom there are no satisfactory alternative treatment options. Dostarlimab is an alternative to pembrolizumab for patients with dMMR metastatic CRPC that has progressed following prior treatment for whom there are no satisfactory alternative treatment options.
- A variety of experimental immunotherapies are being tested in prostate cancer, including chimeric antigen receptor (CAR)-T cell therapies, and eligible individuals should be encouraged to enroll in available trials testing new strategies.



(Left to Right) Darren Sachs, DO - Phillip D. Reid, MD - Aamer Farooq, MD

Prevention

There is no guaranteed way to prevent prostate cancer, but there are some things you can do to reduce your risk:

- **Eat a healthy diet:** A diet low in fat and red meat and high in fruits, vegetables, and whole grains may help reduce your risk of prostate cancer.
- **Maintain a healthy weight:** Being overweight or obese can increase your risk of prostate cancer.
- **Exercise regularly:** Regular physical activity can help reduce your risk of prostate cancer.
- **5-AR inhibitors** decrease, but do not eliminate, the risk of prostate cancer. There is scant information about whether these agents reduce the risk of death from prostate cancer or affect overall survival.
- **Consider screening:** Talk to your doctor about prostate cancer screening, including PSA testing and DREs. Early detection and treatment can improve your chances of a successful outcome.



Brian Canavan, DO



Seema Varma, MD



Bruno Fang, MD

Astera Cancer Care Opens New Location in Toms River

On October 1, 2024, Astera Cancer Care proudly opened a temporary location at 601 Route 37 West, Suite 101, in Toms River, New Jersey. Astera Cancer Care is proud to serve the Toms River community and is working toward the opening of our new state-of-the-art facility.

"The opening of our Toms River location allows us to expand our reach to Ocean County and enhance our ability to serve patients across New Jersey," said Edward J. Licitra, MD, PhD, Chairman and CEO of Astera Cancer Care. "We are committed to making high-quality cancer care more accessible to those who need it most."

The Toms River site is staffed by a dedicated

team of expert physicians. Dr. Seema Varma is a board-certified oncologist-hematologist, at the new location. Dr. Varma, who completed her residency and fellowship at Staten Island University Hospital, brings a wealth of experience, particularly in the areas of breast cancer, women's health, and palliative care.

"I am honored to join Astera Cancer Care and bring comprehensive, patient-centered cancer care to the Toms River community," said Dr. Varma. "Our team is dedicated to supporting patients throughout their entire cancer journey, providing not only the best treatment options but also an added layer of care and compassion."

Dr. Bruno Fang and Dr. Brian Canavan are also seeing patients at the Toms River location. Dr. Fang will continue to see patients in East Brunswick, and Dr. Canavan will continue to see patients in Edison. Both physicians will join Dr. Varma in ensuring that patients in the Toms River area receive the most effective and advanced cancer treatments.

To make an appointment at the Toms River location, please call 732-390-7750.

For more information about Astera Cancer Care and its services, visit [asteracancercare.org](https://www.asteracancercare.org).

Astera Cancer Care's Infusion and Pharmacy Services: It Matters



At Astera Cancer Care, our commitment to comprehensive, patient-centered care is at the heart of everything we do. Our state-of-the-art infusion and pharmacy centers extend far beyond traditional cancer treatment, offering a range of services designed to improve patient well-being across multiple conditions, including hydration therapy and treatments for other complex disorders. Whether you're battling cancer or managing other health issues, our infusion and pharmacy teams are here to provide the highest level of care and support. Because to us, **It Matters.**

While cancer treatment remains a core part of our mission, we recognize that many patients need specialized infusion services for non-cancerous conditions. Our infusion centers offer a full range of advanced infusion services for conditions such as rheumatoid arthritis, multiple sclerosis, asthma, osteoporosis and many other conditions. These additional services ensure patients receive the vital care they need in a setting focused on comfort, safety, and exceptional medical oversight.

Our in-house infusion pharmacy is a critical component of the care we provide. Managed by a dedicated team of professionals, our pharmacy operates within a highly specialized environment where precision is paramount. Every step of the medication process, from compounding to dispensing, is handled with care, ensuring each dose is accurate and tailored to meet each patient's unique needs.

Our Pharmacy Technicians play a pivotal role in ensuring this accuracy. Their diligence and attention to detail ensure that medications are prepared and administered safely, contributing directly to better patient

outcomes. From customized chemotherapy treatments to supportive medications, the expertise of our technicians is instrumental in delivering high-quality care.

Our pharmacists, working in tandem with healthcare providers, nurses, and financial advisors, offer crucial oversight throughout every stage of the treatment process. They review patient treatment plans, provide guidance on medication therapy, and ensure patients receive the most effective treatments. This level of collaboration ensures that our patients benefit from the highest standards of care while also helping to optimize outcomes and manage any potential side effects.

Behind the scenes, our pharmacy directors and vice president provide the strategic leadership necessary to keep Astera Cancer Care at the forefront of innovation. Their vision and years of experience ensure we continually evolve and improve our practices to ensure every patient receives the safest and most effective therapies. The convenience of having both infusion and pharmacy services in one location enhances

the patient experience and contributes to the overall success of treatment. With easy access to medications and infusion services, patients can focus on their health without the added stress of navigating multiple facilities. Our infusion pharmacy's dedication to individualized, compassionate care sets Astera Cancer Care apart.

At Astera Cancer Care, we understand that every patient's journey is unique. That's why we strive to provide personalized care that meets each patient's needs. By integrating advanced pharmacy services with comprehensive infusion care, we continue to elevate the standard of healthcare, delivering life-changing treatments to all who need them.



Vivica's Fight Against Lymphoma

What began as a small bump in Vivica's pelvic area—a spot she thought was a minor irritation—soon marked the start of a life-changing chapter. Seeking reassurance, she visited her general practitioner, who immediately expressed concern and referred her to Dr. Aysha Khalid of Astera Cancer Care. A biopsy confirmed her fears: stage three follicular lymphoma. Yet, even in that moment of uncertainty, Dr. Khalid offered her hope through her warm bedside manner and access to a cutting-edge treatment that Vivica could only find at Astera Cancer Care.

Dr. Khalid recommended a personalized treatment plan involving a clinical trial—one of the latest advancements in cancer care. Unlike many other facilities without access to clinical trials, Astera provided Vivica the opportunity to bypass chemotherapy and radiation entirely. These treatments often bring debilitating side effects, but Vivica's trial offered a path with minimal to none, allowing her to maintain her strength and well-being throughout her journey.

Clinical trials like the one Vivica participated in are typically only accessible at academic institutions, but Astera has brought that level of advanced care closer to home. The trial gave her access to a promising new drug—one that not only treated her cancer but allowed her to maintain her quality of life throughout the journey.

Throughout her treatment, Vivica was surrounded by a compassionate care team that provided more than medical expertise—they created a supportive and encouraging environment. "The staff, the doctors—everyone treated me with kindness. They welcomed me with open arms, and I just love them all," Vivica said.

Her family, especially her mother—a cancer survivor herself—was her constant source of strength and wisdom. Yet her greatest inspiration came from her 13-year-old son. "I needed to be there for him," she said with determination. Small acts of self-care, like getting her nails done and treating herself to new sneakers, reminded her of the life she was fighting to protect.

Now, with her treatment behind her, Vivica reflects with gratitude on the groundbreaking therapies that transformed her journey. She looks ahead with optimism, envisioning a future where she can expand her family and create cherished new memories. Her experience—shaped by access to advanced, innovative care—has given her more than just a second chance at life; it has restored her hope for the future.



Clinician Engagement

Strategies to Increase Palliative Care Access in a Multi-Site Community Oncology Practice: A Patient-Focused Perspective

Palliative care is an essential, yet often underutilized, service in oncology that focuses on improving the quality of life for patients at all stages of serious illness, particularly those with advanced cancer. Recognizing this gap, Astera Cancer Care developed and implemented clinician engagement strategies to increase palliative care access across its multi-site oncology practice.

The recent study, led by our dedicated team, including Advanced Certified Hospice and Palliative Nurse Practitioner Tina Basenese, sheds light on these efforts and highlights the life-changing impact of early palliative care access for patients and their families. In October, NP Basenese presented this work at the ASCO Quality Symposium.

Why Access to Palliative Care Matters

Despite nearly two decades since palliative care was recognized as a medical subspecialty, it remains misunderstood by many oncologists, often conflated with hospice care. This misconception results in late or even non-existent referrals to palliative care, depriving patients and families of the comprehensive support they need during their cancer journey. However, extensive research has demonstrated that early palliative care for patients with advanced cancer improves treatment compliance, decreases hospitalizations, enhances patient and family experiences, and ultimately leads to longer, higher-quality lives.

Palliative care isn't just for end of life. It's about ensuring patients live as comfortably and fully as possible, even while managing serious illnesses. At Astera Cancer Care, we're committed to changing the narrative around palliative care by making it a standard part of care for our patients.

Study Highlights: Implementing Strategies for Change

The study was conducted between September 2023 and April 2024 across our eight medical oncology offices. This study focused on increasing awareness of palliative care consults for all clinical staff, reminders to providers in different ways and encouraging earlier referrals. Key strategies were implemented, including:

- 1 Weekly MD/APP Huddles** - Clinicians regularly reviewed the palliative care needs of all our patients during team meetings, fostering an open dialogue about how to best support each patient.
- 2 Nursing and Social Work Referrals** - Nurses and social workers were empowered to make direct palliative care referrals, ensuring patients didn't have to wait for physician approval to access this vital service.
- 3 Advance Care Planning** - Advanced Practice Providers (APPs) facilitated discussions with patients about their care preferences, allowing for earlier and more informed palliative care planning.
- 4 Proactive Chart Reviews** - Palliative care specialists reviewed patient charts to proactively identify those who might benefit from palliative care and recommended referrals to oncologists and APPs.
- 5 Timely Scheduling** - Our team works to hardwire processes that ensured prompt scheduling of palliative care referrals, making access smoother and more efficient.



Sally Johnson, Advanced Practice Provider (Left)

Clinician Engagement

Strategies to Increase Palliative Care Access in a Multi-Site Community Oncology Practice: A Patient-Focused Perspective

Results: A Positive Impact for Patients


The results of these strategies have been encouraging. During the intervention period, there was a 56% increase in palliative care referrals across the practice, with referrals rising from 1.8% to 2.8% of unique cancer patients. More significantly, the number of newly diagnosed advanced cancer patients who received early palliative care referrals (within eight weeks of diagnosis) increased by 50%.

These results highlight that by empowering our clinical teams and integrating palliative care into routine oncology care, we can provide earlier and more comprehensive support to patients and their families. Early palliative care offers patients a chance to better manage symptoms, maintain quality of life, and focus on what matters most during their treatment journey.

Tina Basenese, who authored the abstract, emphasized the importance of collaboration across the care team in achieving these results: "By fostering collaboration among the entire care team, we're raising awareness and ensuring that patients in need receive the appropriate support. Engaging everyone in identifying those needs made such a difference in increasing access for many people."



Tina Basenese, MA, APN, ACHPN



Looking Forward: The Future of Palliative Care at Astera

The success of this initiative marks a cultural shift within our practice. As attitudes and behaviors continue to change, palliative care will become a standard part of treatment for all patients with advanced cancer. Moving forward, we aim to assess patient and family satisfaction with their care. By aligning treatments with patient wishes and providing holistic support, we can create a more compassionate, patient-centered approach to oncology care.

At Astera Cancer Care, we believe every patient deserves access to the highest standard of care, including timely palliative care. With ongoing efforts to engage clinicians and expand access, we are dedicated to making palliative care an integral part of the patient experience, ensuring that everyone receives the support they need when they need it most.

Minimizing Radiation
Side Effects with

Prostate Spacer Balloons

Prostate cancer treatments have become increasingly effective over recent years, especially with advancements in radiation therapy. This treatment option provides excellent 10-year survival rates for prostate cancer patients, boasting rates of 98% for low-risk disease, 97% for intermediate-risk disease, and 90% for high-risk disease. However, like any medical intervention, radiation treatment has the potential for side effects. At Astera Princeton Radiation Oncology, we are committed to minimizing these side effects with innovative solutions, including prostate spacer balloon devices like the BioProtect Balloon.

Radiation therapy targets cancer cells with high precision, effectively eliminating tumors in many prostate cancer cases. Radiation affects and destroys cells that are dividing (cancer cells) but still may injure normal healthy tissues, and this can impact on nearby organs and lead to complications such as rectal bleeding, pain, or ulcers. Rectal toxicity may significantly impact a patient's quality of life. By strategically placing the BioProtect Balloon, we can significantly reduce the chances of this complication.

How the BioProtect Balloon Protects Patients

The BioProtect Balloon is a biodegradable spacer that gently moves the rectum away from the prostate. Its absorbable material resembles surgical thread used in absorbable sutures and remains in place during radiation treatment, gradually dissolving and being safely absorbed by the body afterward.

In practice, this spacer acts as a protective barrier, minimizing the radiation exposure to surrounding non-cancerous tissues, particularly the rectum. This innovative device has shown considerable efficacy in clinical studies, with the BioProtect Balloon reducing unintended radiation exposure in 97.9% of patients. By protecting rectal tissue, the BioProtect Balloon helps to lower the risk of complications and allows patients to undergo treatment with greater confidence.



(Left to Right) Edward Soffen, MD - Joseph Pepek, MD - Hiral Fontanilla, MD - Victor Ng, MD

Who Benefits from the BioProtect Balloon?

Patients with prostate cancer have benefitted from the BioProtect Balloon, seeing improved outcomes and fewer side effects from their radiation therapy. This device has been a powerful tool in enhancing prostate cancer treatment by protecting patients' health and quality of life. It is available at our Monroe office.

Our team is dedicated to helping you achieve the best possible outcome with the latest advancements in cancer treatment technology. If you're seeking a proactive approach to minimize side effects and protect your healthy tissues during prostate cancer treatment, the BioProtect Balloon might be the solution you're looking for. Consult with your radiation oncologist for more information about the BioProtect Balloon and to determine whether it may be right for you.

The Evolving Landscape of Breast Cancer Treatment



Sundus Abbasi, DO

In recent years, breast cancer treatment has witnessed groundbreaking changes, both in surgical approaches and broader patient care. These advancements allow for improved quality of life with less invasive options.

Dr. Sundus Abbasi, a renowned breast surgeon at Astera Breast Care, discusses how these advancements are reshaping the patient experience.

“Looking at breast surgery from when it first started,” Dr. Abbasi began, “we’ve come a long way. Initially, women faced radical procedures like full mastectomies and extensive lymph node dissections. This left patients with physical defects and, oftentimes, chronic conditions, such as lymphedema, which significantly affected their quality of life. Today, due to the advancements in our adjuvant techniques and quality of imaging, we can offer breast conservation.”

One of the most significant shifts in breast cancer treatment is the emphasis on oncoplastic surgery. This method combines cancer surgery with plastic surgery techniques to improve cosmetic outcomes while achieving optimal cancer control. “The emphasis on oncological surgery is now how to treat cancer while considering the impact on a patient’s quality of life,” explained Dr. Abbasi. “We’re using innovative techniques that allow patients to keep their breast shape or even have a reduction or lift, creating a more natural result post-surgery.”

Oncoplastic surgery provides a means for patients to feel whole, preserving their physical health and self-image. “Patients undergoing lumpectomies now have options that didn’t exist before,” Dr. Abbasi continued. “For instance, if a woman has larger breasts and needs a lumpectomy, we

can perform a reduction at the same time. These techniques have really expanded our ability to support patients in ways that are both medically effective and emotionally supportive.”

Alongside improvements in surgical aesthetics, the approach to lymph node management has also transformed. One major change involves the axillary lymph nodes, which drain the breast, which are often sampled to check for cancer spread. “In the past, we removed all the lymph nodes, which often led to chronic swelling known as lymphedema,” Dr. Abbasi stated. “Today, we have a more selective approach. Thanks to improvements in imaging and systemic therapies like chemotherapy and radiation techniques, we can remove fewer nodes without compromising cancer outcomes.”

Advancements in imaging technology play a key role in this shift toward less invasive procedures. “Nearly every patient now has access to 3D breast imaging, supplemented with ultrasounds or MRIs if there’s anything concerning,” she noted. “We’re able to detect cancer much earlier, which allows us to take a less aggressive surgical approach and reduce the likelihood of lifelong side effects, such as lymphedema.”

Dr. Abbasi emphasized that regular screenings are crucial to catching cancers early. “Many patients are hesitant to get their mammograms because they fear what they might find,” she admitted. “But the reality is that with our current technology, finding cancer early often means more options for surgery and less aggressive treatments. It’s so important for people to understand that screening doesn’t just detect cancer; it allows us to treat it in the least invasive way possible.”

These advancements have led to a decrease

in mastectomies and chemotherapy, Dr. Abbasi emphasized, particularly in cases of early detection. “Most patients are no longer losing their breasts or undergoing chemotherapy because we’re catching cancers early. It’s a really reassuring shift for patients to know that even if their screening detects something, they have a wide array of options to address it.”

“It’s an exciting time in breast cancer treatment,” Dr. Abbasi said. “And the best part is knowing that we’re able to provide options that allow patients to maintain their quality of life and feel whole through their journey.”

With early detection and innovations in breast cancer treatment, the landscape of care is changing. Today, a breast cancer diagnosis can mean more options, less invasive treatments, and, most importantly, hope for the future. By staying proactive with screenings, patients empower themselves to take full advantage of these evolving treatment options, helping them live healthier, fuller lives.



Lisa A. Hopkins, MD

American Cancer Society's Making Strides Walks

Jersey City & Edison

In October, Team Astera walked together in this year's American Cancer Society's events in Jersey City and Edison, uniting to support patients and advance cancer research. Thanks to the incredible efforts of our teams, we collectively raised almost \$10,000!

Our doctors, patients, staff, and friends showed up in full support of our mission to eradicate breast cancer, embodying our commitment to meaningful community initiatives.


Thank you to everyone who joined us!







First Patient in the World Enrolled in IDeate-Lung02



Percy L. Yeung, PhD, CCRP

Astera Cancer Care, an independent, physician-owned multi-specialty oncology practice, has yet again achieved another significant milestone by enrolling the world's first patient in phase 3 of the IDeate-Lung02 clinical trial. This

groundbreaking study aims to compare the efficacy and safety of Infinatamab Deruxtecan (I-DXd) with physician's choice of chemotherapy standard treatments chosen by physicians for patients with relapsed small cell lung cancer (SCLC). Conducted across 229 global sites, this trial highlights Astera's commitment to advancing cancer treatment and research, marking a historic moment as they lead the way in this critical clinical study.

IDeate-Lung02 is enrolling patients with relapsed small cell lung cancer (SCLC) who are 18 or older, have received a prior platinum-based treatment, and must have measurable cancer that has progressed.

The trial utilizes two primary measures to assess the effectiveness of the treatments: Objective Response Rate (ORR) and Overall

Survival Rate (OS). ORR evaluates how well the cancer responds to the treatment by examining the percentage of patients whose tumors shrink or disappear after receiving therapy. OS measures the length of time in which patients live from the start of treatment.

The trial also explores various secondary objectives to better understand the efficacy and safety effects of Infinatamab Deruxtecan (I-DXd). These include evaluating how patients feel and function while on the drug in order to determine if the drug triggers an immune response by being recognized by the body as a foreign object, as well as monitoring any changes in the levels of B7-H3, a protein believed to have potential involvement in cancer progression. Additionally, the study strives to characterize the pharmacokinetics of I-DXd, involving the understanding of how the drug is processed and absorbed by the body.

Astera Cancer Care is dedicated to providing patients with cutting-edge treatments and advancing the field of cancer research. Those interested in participating in these clinical trials can find the eligibility criteria on clinicaltrials.gov (NCT06203210).

To make an appointment at Astera Cancer Care, please call (732) 390-7750.

2024 New Physicians

We're excited to introduce a group of new physicians, each bringing specialized expertise and a commitment to enhancing cancer care with personalized, compassionate treatment. From advancing clinical research to providing comprehensive support, these doctors are dedicated to guiding patients through every stage of their journey.



Nandini Ignatius, MD

Nandini Ignatius, MD

Locations: Monroe and Robbinsville

Dr. Ignatius earned her Bachelor of Medicine and Surgery from Bangalore Medical College in India and completed her internal medicine residency at John H. Stroger Jr. Hospital of Cook County, followed by a Hematology/Oncology fellowship at the University of Illinois at Chicago. Dr. Ignatius speaks English and Hindi.



Ghazal Habib Kango, MD

Ghazal Habib Kango, MD

Locations: East Brunswick and Monroe

Dr. Kango received her medical degree from the George Washington University of Medicine. She completed her internal medicine residency at the George Washington University Hospital, where she served as chief resident. Dr. Kango completed a Hematology and Oncology fellowship at the University of Maryland Medical Center. Dr. Kango speaks English, Kashmir, and Urdu.



Dhaval H. Patel, MD

Dhaval H. Patel, MD

Location: Edison

Dr. Patel earned his Bachelor of Medicine and Surgery from Pramukhswami Medical College in India, completed an Internal Medicine Residency at The Wright Center for Graduate Medical Education, and a Hematology/Oncology Fellowship at the Jefferson Health - Einstein Medical Center. Dr. Patel speaks English, Gujarati, and Hindi.




Seema Varma, MD

Seema Varma, MD

Locations: Toms River

Dr. Varma earned her medical degree from the University of Mumbai. She completed her residency and fellowship from Northwell Health/Staten Island University Hospital. Dr. Varma speaks English, Hindi, Marathi, Gujrati, and Urdu.



Siu-Long Yao, MD

Siu-Long Yao, MD

Medical Director of Clinical Research

Locations: East Brunswick, Edison

Dr. Yao received his medical degree from Yale University School of Medicine, followed by an internship and residency at the Geisel School of Medicine at Dartmouth. He completed his Hematology/Oncology Fellowship at Johns Hopkins University School of Medicine. Dr. Yao speaks English and Mandarin.

Patient Reviews

“Dr. Dobrescu, nurses and entire staff are absolutely wonderful. I feel at ease with them during difficult time. I would recommend them, Astera, to anyone.”

“Can't say enough about how wonderful Dr. Hopkins and her entire staff team are. They are top quality, professional, and beyond everything, the most kind, welcoming, brilliant people.”

“Staff are super helpful and friendly, and competent, receptionists, phlebotomists, intake folks, care advisors, telemeds, especially doctors.”

“Everyone in this office from the doctors and nurses to the phlebotomist and techs and front office staff are wonderful, caring amazing people. It's really great to go to the oncologist's office and get good news, then get better news, then get the best news! My numbers are all great! Thank you, Dr. Ronnen.”

“Absolutely 10+ in Service Rating? Here is my observation! The office Nether Staff I find...
CLEAN! CURIOUS! FRIENDLY! INTELLIGENCE! INTEGRITY! PATIENCE! PROFESSIONAL! PROMPT! RESPECTFUL-ABLE! From the intake Front Desk both Stephanie and Kelly who are absolutely Warm, Welcoming and Very Friendly! Then you are greeted warmly by a wonderful Service team of executional Technicians By the names of, Genesis, Gloria, Vivian and, Subapaude. These women are Great Hematologist, then I met Ericka who is an accommodating and highly respectable scheduler. The women are dressed well and very neat; their appearance are very pristine and well manicured absolutely professional in their work scrubs. These women work very synchronized and respectfully of one another! Dr. Jieqi Liu is a kind force to be reckoned with, her bedside manner, her listening, her hearing and caring ability are matchless in my, conclusion Dr. Liu is gracious, generously humbled accompanied with a Great Intellectual intelligence and diligence for her patients and herself! Astera is Great Place and a Safe Place for addressing You and your health care needs! Thanks so Very Much, May GOD Bless each of you richly (Health, Peace of Mind, Safety and Joyful Heart)”

“Dr Abbasi was wonderful....took the time to explain everything in detail.....the entire staff was super friendly too !!!”

“Absolutely positively phenomenal superstars.”

“There are not enough words to describe the caring atmosphere created for you. Giving you the sense of being among friends and you are safe. They explain everything until you are sure you understand. All the while making you feel comfortable and assuring you of all possibilities. I cannot thank them enough for their expertise and kindness.”

“This July I took myself to the ER at a local hospital for constant vomiting and not being able to keep any food down. Upon many tests, it was determined I had cancer. Yes, the big CA. Felt like a bad dream at first and then the reality set in. I was introduced to an oncologist by the name of Dr. Brian Canavan and his team. Dr. Canavan sat with me, drew pictures explaining the disease and the ways that going forward could cure my cancer. I have had my second round of chemotherapy at Astera and I cannot give this facility enough praise. Everyone here is so professional and caring. The nurses in the infusion room are like angels on earth. They give hope, hugs, and always a positive attitude. Dr, Canavan has given me the courage to not give up. His staff and himself are available 24/7. Although I have a long road ahead of me, I believe I will beat this and be able to ring the bell at the end. THANK YOU Dr. Brian Canavan and all at Astera for helping me on this journey. Angels do walk in this place.”

“Dr. Jin Lee and the entire team are extremely responsive, efficient, and pleasant. Honestly the best medical experience I think I've had, from new patient intake and ease of making an appointment to the doctor himself and the follow through. Dr. Lee listened to my concerns, presented possible treatment plans, and then personally communicated my lab work results less than 24 hours later.”

“Very nice experience, staff very pleasant, clean office, Dr. Varma very caring and friendly, knowledgeable about your condition, will recommend to anyone that needs her expertise in oncology and Hematology.”

“Dr. Robert Fein is the best oncologist I have ever met. Dr. Robert Fein #1, and with great experience. When I arrived at his consultation, my life changed... from that moment on, Dr. Robert Fein and his entire team gave me special attention, now I consider them like family. Dr. Robert Fein, his colleagues, nurses and team at Astera are very professional, friendly and high-tech. I am sure that they gave me the most appropriate and effective treatment for my case... they are always looking out for you and follow you up all the time and help you with additional resources if necessary. It was the best experience I have ever had in that difficult and learning moment. All my respect, admiration and gratitude to Dr. Robert Fein and his team. I owe them my life and my eternal gratitude... I highly recommend them....”

Upcoming Virtual Programs

1/13/25 : Life and Legacy




Facilitated by: **Larriesa Smith, LCSW**

People who have a cancer diagnosis often reflect on their life decisions, the meaning in their lives and how they want to be remembered. Learn tips for tackling some of these difficult processes.

1:00pm



2/10/25: For Parents: Talking with Children About Cancer



Facilitated by: **Neshama Marcus, LCSW, OSW-C**

Explore and practice age-appropriate strategies to communicate with children about cancer diagnoses.

1:00pm



3/10/25: Building Family Caregiver Capacity in the Cancer Journey



Facilitated by: **Sharlynn Flores, LCSW**

Understanding your capacity as a family caregiver is essential for both your well-being and the quality of care provided to the patient throughout the cancer journey.

1:00pm



4/15/25: Tips for Finding Work-Life Balance with Cancer




Facilitated by: **Brooke Murphy, BSW**

Learn strategies to exercise patience in yourself, better manage day-to-day tasks, prioritize and maintain overall well-being, and achieve peace of mind.

1:00pm



5/12/25 : Tobacco and Cancer



Facilitated by: **Sharon Zarate, LCSW**

The relationship between tobacco cessation and cancer is significant and complex. Tobacco cessation is a vital part of cancer care, promoting better health for both at-risk individuals and those currently battling cancer.

1:00pm



Upcoming Virtual Support Groups

Virtual Caregiver Support Group



Facilitated by: **Larriesa Smith, LCSW - Neshama Marcus, LCSW, OSW-C**

A gathering designed to provide emotional, informational, and practical support to individuals who care for someone diagnosed with cancer. This group provides a safe and welcoming environment where caregivers can share their experiences, feelings, and challenges with others who understand their situation.

11:00am-12:00PM 4th Friday of Every Month

Virtual Breast Cancer Support Group (all stages)



Facilitated by: **Larriesa Smith, LCSW - Brooke Murphy, BSW - Neshama Marcus, LCSW, OSW-C**

Advance registration for this group is required

Zoom Link provided upon registration prior. Maximum registration for the group is 12 participants.

4:00pm-5:00pm Wednesdays, 1/8/25 - 2/26/25 (8 weeks)

Virtual General Cancer Support Group (all stages)



Facilitated by: **Sharon Zarate, LCSW - Neshama Marcus, LCSW, OSW-C**

Advance registration for this group is required

Zoom Link provided upon registration prior. Maximum registration for the group is 12 participants.

4:00pm-5:00pm Wednesdays, 4/23/25 - 6/11/25 (8 weeks)



Sharon Zarate, LCSW



To register for upcoming virtual programs, scan QR Code or visit: asteracancercare.org

Locations

Medical Oncology

Bridgewater

P: 732-390-7750

1200 US Highway 22 East, 3rd Floor
Bridgewater, NJ 08807

East Brunswick

P: 732-390-7750

629 Cranbury Road, 2nd floor
East Brunswick, NJ 08816

Edgewater

P: 732-390-7750

1829 Hudson Park
Edgewater, NJ 07020

GPS: 235 Old River Road
Edgewater, NJ 07020

Edison

P: 732-390-7750

3 Progress Street, Suite 100
Edison, NJ 08820

Jersey City

P: 732-390-7750

1 Exchange Place
Jersey City, NJ 07302

Monroe Township

P: 732-390-7750

9 Centre Drive, Suite 100
Monroe Township, NJ 08831

Robbinsville

P: 732-390-7750

1 Washington Boulevard, Suite 9
Robbinsville, NJ 08691

Rutherford

P: 732-390-7750

201 RT 17 North, FL 11
Rutherford, NJ 07070

Somerset

P: 732-390-7750

75 Veronica Avenue, Suite 201
Somerset, NJ 08873

Toms River

P: 732-390-7750

601 Route 37 West, Suite 101
Toms River, NJ 08755



(Left to Right) Aamir Zaman, MD - Joel Alcid, MD - Jin Lee, MD

Locations

Radiation Oncology

Darby

Mercy Fitzgerald Hospital Department of Radiation Oncology

P: 610-237-4370

1500 Lansdowne Avenue Medical Science Building, Lower Level Darby, PA 19023

Flemington

Hunterdon Regional Cancer Center Department of Radiation Oncology

P: 908-788-6514

2100 Wescott Dr, Flemington, NJ 08822

Freehold

CentraState Medical Center Department of Radiation Oncology

P: 732-303-5290

901 West Main St, Freehold NJ, 07728

Langhorne

St. Mary Regional Cancer Center Department of Radiation Oncology

P: 215-710-5300

1201 Langhorne-Newtown Road, Langhorne, PA 19047

Monroe Township

P: 609-655-5755

9 Centre Drive, Suite 115, Monroe Township, NJ 08831

New Brunswick - Saint Peter's University Hospital

P: 732-745-8590

215 Easton Avenue, New Brunswick, NJ 08901

Plainsboro

Penn Medicine Princeton Medical Center

P: 609-853-6770

1 Plainsboro Road, Plainsboro, NJ 08536

Somerset

ProCure Proton Therapy Center

P: 732-357-2600

103 Cedar Grove Lane, Somerset, NJ 08873

Locations

Breast Surgery

Edgewater

P: 732-390-7750

1829 Hudson Park Edgewater NJ 07020

GPS: 235 Old River Road Edgewater, NJ 07020

Jersey City

P: 732-390-7750

1 Exchange Place, Jersey City, NJ 07302

Monroe Township

P: 732-390-7750

9 Centre Drive, Suite 100, Monroe Township, NJ 08831

New Brunswick

The Breast Center Saint Peter's University Hospital

P: 732-846-3300

CARES Building 240 Easton Avenue, 3rd Floor, New Brunswick, NJ 08901

Rutherford

P: 732-390-7750

201 RT 17 North, FL 11, Rutherford, NJ 07070



Lisa A. Hopkins, MD



Seeta Trivedi, MD and Joshua D. Oderanti, DNP-BC

OUR PATIENTS & THEIR FAMILIES MATTER

Our patients and their families tell the story of overcoming cancer like no other. They help us connect, inspire, and empower. If you know a patient or have a family member who would like to make an impact and share their experience with us, please have them contact dorothy.ballweg@asterahealthcare.org.

